pharma news today obesity drugs glp-1 september 2025 IQVIA Early Bird: Revealed - The Trends Shaping Pharma's Future The cost of manufacturing GLP-1

Recuperacin neurolgica: Se ha probado en modelos de ictus, lesin medular o trastornos del movimiento en animales, con resultados prometedores

Possible biases caused by the randomization process, deviations from intended interventions, missing data, outcome measurements, and selective reporting were rated as high risk, low risk, or some concerns

As of 2019, an estimated 4.8 million newborns are affected by iodine deficiency disorders each year (6)

Em estudos pr-clnicos, avaliado quanto sua influncia em regulao de colgeno, atividade antioxidante celular e processos inflamatrios experimentais, no sendo destinado a consumo humano ou aplicao teraputica